Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study.
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms RAPIDA
- Sponsors AbbVie
- 07 Jun 2017 Biomarkers information updated
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Nov 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.